Key Points
- Director Larry Padfield sold 1,030 shares at $81.84 on Feb. 20 for $84,295.20, cutting his position by 10.8% to 8,508 shares, according to an SEC filing.
- Quarterly results showed EPS of $1.50 beating the $1.26 consensus, but revenue of $455.6M missed estimates and declined 2.4% year‑over‑year.
- Analyst sentiment is mixed—Weiss and Wall Street Zen upgraded while Zacks downgraded to "strong sell"—and MarketBeat's average rating is "Reduce"; the stock has a ~$1.97B market cap and a 52‑week range of $70.10–$105.60.
Innospec Inc. (NASDAQ:IOSP - Get Free Report) Director Larry Padfield sold 1,030 shares of Innospec stock in a transaction dated Friday, February 20th. The shares were sold at an average price of $81.84, for a total value of $84,295.20. Following the transaction, the director owned 8,508 shares of the company's stock, valued at $696,294.72. The trade was a 10.80% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Innospec Stock Up 0.4%
Shares of IOSP opened at $79.30 on Wednesday. The company has a market capitalization of $1.97 billion, a price-to-earnings ratio of 16.94 and a beta of 0.91. Innospec Inc. has a 52 week low of $70.10 and a 52 week high of $105.60. The stock's 50-day moving average price is $81.20 and its 200-day moving average price is $79.29.
Innospec (NASDAQ:IOSP - Get Free Report) last announced its quarterly earnings results on Tuesday, February 17th. The specialty chemicals company reported $1.50 earnings per share for the quarter, beating the consensus estimate of $1.26 by $0.24. Innospec had a return on equity of 10.18% and a net margin of 6.56%.The company had revenue of $455.60 million during the quarter, compared to analysts' expectations of $460.87 million. During the same period last year, the business earned $1.41 earnings per share. Innospec's quarterly revenue was down 2.4% on a year-over-year basis. As a group, equities analysts anticipate that Innospec Inc. will post 6.18 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of analysts recently issued reports on the stock. Weiss Ratings raised shares of Innospec from a "sell (d+)" rating to a "hold (c-)" rating in a report on Thursday, February 19th. Zacks Research downgraded shares of Innospec from a "hold" rating to a "strong sell" rating in a research report on Thursday, February 19th. Finally, Wall Street Zen raised shares of Innospec from a "hold" rating to a "buy" rating in a research note on Saturday, December 13th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Innospec currently has an average rating of "Reduce".
Get Our Latest Research Report on IOSP
Institutional Investors Weigh In On Innospec
A number of institutional investors have recently added to or reduced their stakes in the stock. BNP PARIBAS ASSET MANAGEMENT Holding S.A. purchased a new stake in Innospec in the 2nd quarter worth $28,000. Versant Capital Management Inc grew its position in shares of Innospec by 378.1% in the third quarter. Versant Capital Management Inc now owns 545 shares of the specialty chemicals company's stock valued at $42,000 after purchasing an additional 431 shares during the period. Hantz Financial Services Inc. increased its stake in shares of Innospec by 271.0% during the fourth quarter. Hantz Financial Services Inc. now owns 575 shares of the specialty chemicals company's stock worth $44,000 after purchasing an additional 420 shares in the last quarter. EverSource Wealth Advisors LLC raised its position in shares of Innospec by 1,159.5% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 529 shares of the specialty chemicals company's stock worth $44,000 after purchasing an additional 487 shares during the last quarter. Finally, Allworth Financial LP lifted its stake in Innospec by 31.0% in the 3rd quarter. Allworth Financial LP now owns 588 shares of the specialty chemicals company's stock valued at $45,000 after buying an additional 139 shares in the last quarter. Institutional investors and hedge funds own 96.64% of the company's stock.
About Innospec
(
Get Free Report)
Innospec Incorporated (NASDAQ: IOSP) is a global specialty chemicals company headquartered in Cleveland, Ohio. The company operates through three principal business segments: Fuel Specialties, Oilfield Services, and Performance Chemicals. In the Fuel Specialties segment, Innospec develops and supplies additives designed to enhance octane levels, improve combustion efficiency, reduce emissions and prevent deposit formation in gasoline and diesel engines. Its Oilfield Services division provides chemical technologies—such as surfactants, corrosion inhibitors and demulsifiers—to support exploration, drilling, production optimization and enhanced oil recovery operations.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
